A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
The study consists of a Core Part (6-months double-blind treatment) and an Extension Part (up to 60-month open-label treatment).
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
novartis.email@novartis.com1-888-669-6682
+41613241111
Phoenix, Arizona 85013, United States
nrsresearch@nrcaz.com
Washington D.C., District of Columbia 20010-2975, United States
East Lansing, Michigan 48824, United States
Caba, C1055AAF, Argentina
Capital Federal, C1023AAB, Argentina
Shinjuku Ku, Tokyo 160-0023, Japan
Santiago Compostela, A Coruna 15706, Spain
kosgood@honorhealth.com+1 480 323 3990
avasquez@fullertonneuro.net+1 714 738 0800
nahmed@advmedresearch.com+1 323 865 3900
kbjazevi@hs.uci.edu+1 714 456 2332
jamal.baptista@adventhealth.com+1 415 600 3604
anu.r.bhooshan@medstar.net
Gabrielle@sfmresearch.com+1 561 939 0300
dordaz@associatesinresearch.com+1 305 246 0873
admin@naparesearch.com+1 407 647 5996
samuel.pierrelouis@adventhealth.com+1 407 303 6729
tanya.nso@outlook.com+1 941 400 4578
deekshitha.turaka@bsd.uchicago.edu
barbera@epilepsydc.com
imccarthy2@mgh.harvard.edu
alexaub@msu.edu
amattle@dentinstitute.com+1 716 887 4799
payne2ka@ucmail.uc.edu+1 513 475 8730
hastind@ccf.org
niizawaga@upmc.edu+1 412 692 4920
davernon@houstonmethodist.org+1 713 441 9484
christina.grunhayes@uth.tmc.edu
tkaycie@uw.edu+1 206 685 1048
Emily.barraza@cndmilwaukee.com